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Abstract
HIV increases risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). The effect of HIV on
presentation, treatment, and outcomes of NHL and HL in routine care in the combination antiretroviral therapy
(cART) merits further characterization. We performed a retrospective analysis of HIV-infected patients with
NHL and HL receiving care at the University of North Carolina at Chapel Hill from January 1, 2000 until
December 31, 2010. Statistical analyses were conducted using SAS, version 9.2 (SAS Institute Inc). Sixty-five HIV-
infected patients with NHL and HL were identified. Patients with non-CNS NHL and HL presented with
advanced disease (85% stage III or IV) and adverse prognostic features. Patients completed 87% of planned
chemotherapy cycles, and 68% of patients completed stage-appropriate therapy. Dose reduction, interruption,
and/or delay occurred during more than 25% of administered cycles in 64% of patients. Infectious complica-
tions, febrile neutropenia, and myelosuppression accounted for 78% of deviations from planned cumulative dose
and dose intensity. Primary CNS lymphoma (PCNSL) was associated with poor prognosis, but 2-year overall
survival was 66% for all non-CNS lymphoma. Among patients surviving at least 2 years, 75% had CD4 count
> 200 cells/ll and 79% had HIV viral load < 400 copies/ml at last follow-up. Despite advanced disease and
difficulty tolerating chemotherapy with optimal cumulative dose and dose intensity, most patients with non-
CNS HIV-associated lymphoma survived more than 2 years after diagnosis, the majority with suppressed
HIV RNA.
Introduction
HIV confers a higher risk of non-Hodgkin lymphoma(NHL) and Hodgkin lymphoma (HL) than occurs in
individuals without HIV.1–3 In the combination antiretroviral
therapy (cART) era, NHL incidence declined but has since
stabilized, while HL incidence has been stable and possibly
even increasing.1,2,4 Additionally, cancer has increased in
frequency as a contributor to HIV mortality, with NHL being
the most frequent cause of cancer-related death.5–8 Pathogenic
mechanisms underlying lymphomagenesis in HIV-infected
persons remain poorly understood, but are postulated to in-
clude B cell dysregulation, perturbations in intracellular sig-
naling, viral coinfections, and decreased cytotoxic T cell
surveillance.9
Risk factors for NHL in HIV-infected individuals include
lower CD4 count and cumulative HIV viremia, whereas a
consistent association between lower CD4 count and in-
creased HL incidence has not been demonstrated, with
there even being some evidence that higher CD4 count
is associated with higher HL and Burkitt lymphoma (BL)
incidence.10–16
Controversy remains as to the optimal lymphoma and
antiretroviral treatment regimens for patients with HIV-
associated lymphoma.17 Clinical trials have demonstrated
comparable outcomes after HIV-associated NHL to patients
without HIV infection.18,19 Extended survival after HIV-
associated lymphoma similar to HIV-uninfected individuals
has also been reported from European observational co-
horts.20,21 However, other studies have found HIV to be an
independent risk factor for death among patients with NHL,
irrespective of stage and histologic subtype.22
If HIV negatively impacts survival after lymphoma diag-
nosis, the mechanisms by which this is mediated are unclear,
and might include more advanced disease, poorer perfor-
mance status, difficulty achieving stage-appropriate chemo-
therapy cumulative dose and dose intensity, reduced
effectiveness or greater toxicity of chemotherapy due to
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interactions with antiretroviral medications, discontinuity or
suboptimal concentrations of antiretroviral therapy due to
interactions with chemotherapy, diminished anti-lymphoma
response of the host immune system, and increased mortality
from lymphoma-unrelated causes. Because interactions be-
tween HIV and lymphoma remain understudied, we under-
took a retrospective analysis of patients with HIV-associated
lymphoma at our institution to characterize their initial pre-
sentation, receipt of HIV and lymphoma treatment, and
clinical outcomes.
Materials and Methods
Patient identification and data collection
We performed a retrospective analysis of HIV-infected
patients with lymphoma receiving care at the University of
North Carolina at Chapel Hill from January 1, 2000 until
December 31, 2010. Patients were identified via comprehen-
sive review of independent, unlinked, institutional HIV and
cancer databases. Data were collected via abstraction from the
medical record. Social Security Death Index records were re-
viewed to ascertain final vital status of patients lost to follow-
up, with patients matched to Death Index records by name
and date of birth. Patients with diffuse large B cell lymphoma
(DLBCL) were compared to an existing institutional research
database of contemporaneously treated adult DLBCL patients
without HIV, without specific matching by calendar year of
diagnosis. Morphologic, immunophenotypic, and molecular
subtypes of DLBCL were analyzed together as a group rather
than separately.
Study definitions
Chemotherapy dose reduction was defined as omission or
dose reduction of any medication included in the treating
regimen. Chemotherapy interruption was defined as discon-
tinuation of all components of an administered cycle before
completion. Chemotherapy delay was defined as failure to
administer a chemotherapy dose on the scheduled date.
Stage-appropriate therapy was defined according to Na-
tional Comprehensive Cancer Center Network (NCCN) clin-
ical practice guidelines for NHL and HL.23,24 For DLBCL,
stage-appropriate therapy was defined as completion of three
or more chemotherapy cycles with radiotherapy or six or
more chemotherapy cycles for Ann Arbor stage I or II disease,
and six or more chemotherapy cycles for stage III or IV dis-
ease. For BL, stage-appropriate therapy was defined as com-
pletion of an NCCN guideline-recommended regimen. For
HL, stage-appropriate therapy was defined as completion of
four or more chemotherapy cycles for stage I or II favorable
disease, four or more chemotherapy cycles with radiotherapy
or six or more chemotherapy cycles for stage I or II unfavor-
able disease, and six or more chemotherapy cycles for stage III
or IV disease. If chemotherapy was stopped due to refractory
lymphoma, this was also considered stage-appropriate ther-
apy. Complete response was defined according to Interna-
tional Harmonization Project criteria.25
Interruption of antiretroviral therapy was defined as dis-
continuation of all medications used to treat HIV lasting at
least 3 days. Change in antiretroviral therapy was defined as
substitution of at least one antiretroviral medication in a
regimen.
Statistical analysis
Statistical analyses were conducted using SAS, version 9.2
(SAS Institute Inc.). Bivariate analyses were conducted using
Fisher’s exact test, two-sample t-test, and Kruskal–Wallis test.
Ethics statement
Our study was approved by the biomedical institutional
review board (IRB) of the University of North Carolina at
Chapel Hill. The requirement for informed consent was spe-
cifically waived by the IRB committee for our study.
Results
Baseline characteristics
Sixty-five patients with HIV-associated lymphoma were
identified (47 NHL, 17 HL, 1 nonclassifiable). Baseline charac-
teristics for NHL and HL patients are shown in Table 1. NHL
cases were primarily composed of DLBCL (n = 17, 41%), pri-
mary CNS lymphoma (PCNSL, n = 12, 29%), and BL (n = 9,
21%). Additionally, there were single cases each of follicular
lymphoma, primary effusion lymphoma, primary cutaneous
lymphoma, and B cell lymphoma not otherwise specified, and
five NHL cases without further histopathologic classification.
There were differences between NHL subtypes with respect to
CD4 count at the time of lymphoma diagnosis, with BL patients
having statistically higher CD4 counts than those with DLBCL
or PCNSL. Of 60 patients for whom HIV diagnosis date was
known, 22 (36%) were diagnosed with lymphoma within 6
months of HIV diagnosis (45% NHL, 12% HL; p = 0.03).
Non-CNS lymphoma cases frequently presented with ad-
verse prognostic features, including impaired performance
status, Ann Arbor stage III or IV disease, abnormal lactate
dehydrogenase (LDH), B symptoms, extranodal and bone
marrow involvement, advanced International Prognostic In-
dex (IPI) in NHL, and advanced International Prognostic
Score (IPS) in HL (Table 2).
Lymphoma treatment
Fifteen of 17 DLBCL patients received chemotherapy.
Chemotherapy regimens included CHOP (cyclophospha-
mide, doxorubicin, vincristine, prednisone; n = 10), CDE
(cyclophosphamide, doxorubicin, etoposide; n = 2), dose-
adjusted EPOCH (etoposide, prednisone, vincristine,
cyclophosphamide, doxorubicin; n = 2), and hyper-CVAD
(cyclophosphamide, vincristine, doxorubicin, dexametha-
sone, alternating with methotrexate and cytarabine; n = 1).
Ten of 17 patients (59%) received rituximab. Four patients
received intrathecal chemotherapy, and four patients received
radiotherapy, one of whom received primary radiotherapy
without chemotherapy for stage IA disease based on co-
morbidities and patient preference. One patient died before
initiation of lymphoma therapy.
All BL patients received chemotherapy. Chemotherapy
regimens included hyper-CVAD (n = 3), CODOX-M/IVAC
(cyclophosphamide, doxorubicin, vincristine, methotrexate,
alternating with ifosfamide, etoposide, cytarabine; n = 2),
CHOP (n = 1), dose-adjusted EPOCH (n = 1), French LMB89
protocol (n = 1), and French LMB86 protocol (n = 1). Five of
nine patients (56%) received rituximab. All patients received
intrathecal chemotherapy.
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Fifteen of 17 HL patients were treated with ABVD (doxo-
rubicin, bleomycin, vinblastine, dacarbazine), 1 patient re-
ceived gemcitabine and carboplatin, and 1 patient received
ChIVPP (chlorambucil, vinblastine, procarbazine, predni-
sone). Two patients received radiotherapy after completing
chemotherapy.
Two of 12 patients with PCNSL received chemotherapy
with the R-MPV regimen (rituximab, methotrexate, procar-
bazine, vincristine). Eight patients received palliative radio-
therapy alone, and 2 patients received no lymphoma therapy.
Chemotherapy administration among 39 patients with
non-CNS lymphoma, for whom detailed records were avail-
able and lymphoma therapy was completed prior to study
conclusion, is summarized in Table 3. Overall, patients com-
pleted 188 of 217 (87%) planned chemotherapy cycles, and 25
patients (64%) completed stage-appropriate therapy as per
NCCN guidelines. Dose reduction, interruption, and/or de-
lay occurred during 71 of 165 cycles (43%) for which data were
available, of which 78% were due to infectious complications,
febrile neutropenia, and myelosuppression (Fig. 1). Of 35
patients for whom data were available, 23 (66%) experienced
chemotherapy dose reduction, interruption, and/or delay
during ‡ 25% of administered cycles.
Of 53 patients with non-CNS lymphoma, 9 (17%) devel-
oped refractory or relapsed lymphoma (7 refractory, 2 re-
lapsed), including 4 DLBCL, 1 BL, 3 HL, and 1 nonspecified B
cell lymphoma. Both relapses occurred late, 5.6 and 8.8 years
after initial diagnosis, in one patient despite continued HIV
RNA suppression. Three refractory or relapsed patients were
treated with salvage chemotherapy (1 DLBCL, 2 HL), with 2
patients proceeding to high-dose chemotherapy with autolo-
gous stem cell rescue (HDT/ASCR).
Interaction of antiretroviral treatment
with lymphoma chemotherapy
HIV treatment records were available during receipt of
lymphoma chemotherapy for 40 patients overall, with 25 pa-
tients either not receiving chemotherapy or receiving HIV
treatment at another facility without available records. Of these
40 patients, 26 (65%) were receiving antiretroviral therapy at
the time of lymphoma diagnosis. Thirty-one (78%) of 40 pa-
tients had HIV RNA results available at lymphoma diagnosis,
of whom 13 (42%) had suppressed HIV RNA < 400 copies/ml.
Twenty of 40 patients (50%) experienced discontinuity of an-
tiretroviral therapy during lymphoma treatment. Ten of 40
patients (25%) had at least one antiretroviral therapy inter-
ruption lasting 3 days or more. Patients experiencing anti-
retroviral therapy interruptions had a mean of 1.2 interruption
events per patient (range 1–3), lasting a median of 33 days per
interruption event (range 4–111 days). Of 28 antiretroviral in-
terruption and/or change events, stated reasons included
gastrointestinal intolerance (n = 8, 29%), virologic failure (n = 5,
18%), interaction with chemotherapy medications (n = 4, 14%),
myelosuppresion (n = 3, 11%), renal insufficiency (n = 2, 7%),
and 1 instance each of financial difficulty, inability to swallow,
transition to hospice, nonadherence, hyperbilirubinemia, and
myalgias. Of 19 antiretroviral interruption and/or change
events in which an individual medication was implicated, the
most frequently implicated agents were ritonavir (n = 9, 47%),
Table 1. Baseline Characteristics of Patients with HIV-Associated Lymphoma
All (n = 65) All NHL (n = 47) DLBCL (n = 17) PCNSL (n = 12) BL (n = 9) HL (n = 17)
Age 42.8 (37.6–48.8) 42.6 (37.4–49.0) 42.2 (37.7–49.1) 43.9 (40.0–48.1) 38.6 (34.3–48.2) 43.6 (38.1–47.8)
Male 80% 81% 88% 67% 89% 76%
Ethnicity
White 28% 32% 47% 8% 44% 18%
African-American 58% 55% 47% 75% 33% 65%
Latino 9% 11% 6% 17% 11% 6%
Other 5% 2% — — 11% 12%
Years since
HIV diagnosis












107 (46–291) 128 (36–316) 112 (46–137) 18 (9–204) 314 (166–548) 73 (55–177)




39% 27% 33% 18% 29% 67%
*p = 0.03 for NHL versus HL.
**p = 0.12 for DLBCL vs. PCNSL, p = 0.01 for PCNSL vs. BL, p = 0.03 for DLBCL vs. BL.
***p = 0.03 for NHL vs. HL.
NHL, non-Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; PCNSL, primary CNS lymphoma; BL, Burkitt lymphoma; HL,
Hodgkin lymphoma.
Median values given with interquartile ranges in parentheses.
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non-ritonavir protease inhibitor (n = 5, 26%), tenofovir (n = 2,
11%), and zidovudine (n = 2, 11%).
Clinical outcomes
Complete response rates and overall survival 2 and 5 years
after lymphoma diagnosis are summarized in Table 4. Of 58
patients for whom at least 2 years had elapsed from lym-
phoma diagnosis on December 31, 2010, 56 patients had as-
certainable vital status with 2 patients (3%) lost to follow-up.
Of 49 patients for whom at least 5 years had elapsed from
lymphoma diagnosis on December 31, 2010, 46 patients had
ascertainable vital status with 3 patients (6%) lost to follow-
up. A complete response was achieved in 36 of 62 patients
(58%) overall (52% NHL, 76% HL; p = 0.15). Survival 2 years
after lymphoma diagnosis was 52% overall (46% NHL, 71%
HL; p = 0.13). Survival was poorest for PCNSL (median sur-
vival 0.2 years), with the longest-surviving patient living 1.5
years after diagnosis. In bivariate analyses, only CNS lym-
phoma versus non-CNS lymphoma was independently as-
sociated with mortality 2 years after lymphoma diagnosis.
Patients with non-CNS lymphoma had significantly better
complete response rates (72% versus 0%; p < 0.0001) and 2-
year survival (66% versus 0%; p < 0.0001) than those with CNS
lymphoma. All three patients with non-CNS lymphoma who
received salvage therapy for relapsed or refractory disease
were alive at last follow-up, including one HL patient treated
with salvage chemotherapy alive 7.0 years after relapse, one
HL patient treated with salvage chemotherapy and HDT/
ASCR alive 0.2 years after ASCR, and one DLBCL patient
treated with salvage chemotherapy and HDT/ASCR alive 0.4
years after ASCR.
Twenty-six of 34 patients (76%) who died had an ascer-
tainable cause of death. Of these, 19 (73%) were due to pro-
gressive lymphoma, 4 (15%) were due to potentially
treatment-related causes (2 deaths from neutropenic sepsis, 1
death from liver failure and disseminated tuberculosis prox-
imate to receipt of chemotherapy, 1 death from liver and
kidney failure proximate to receipt of chemotherapy), and 3
deaths (12%) were unrelated to either lymphoma progression
or treatment (1 death from pneumonia and metastatic anal
squamous cell carcinoma, 1 death from liver failure and he-
patocellular carcinoma, 1 death from cardiac arrest and hyp-
oxemia), all occurring more than 2 years after lymphoma
diagnosis with no evidence of relapsed lymphoma or recent
lymphoma therapy.
Among 34 patients for whom HIV RNA results were
available 6 months after lymphoma diagnosis, 26 (76%) had
HIV RNA < 400 copies/ml (72% NHL, 89% HL, p = 0.40).
Among 29 patients surviving at least 2 years after lymphoma
diagnosis, 15 of 20 (75%) for whom data were available had a
CD4 cell count > 200 cells/ll, and 15 of 19 (79%) had HIV
RNA < 400 copies/ml at last follow-up.
Comparison of HIV-associated DLBCL
with non-HIV DLBCL
Patients with HIV-associated DLBCL were compared to an
existing institutional database of 69 contemporaneously
Table 3. Chemotherapy Administration








Total 82 55 80
Per patient 5.5 6.1 5.3
Cycles completed
Total 75 50 63
Per patient 5.0 5.6 4.2
% completed 91% 91% 79%
Rituximab
% of cycles 52% 56% —
% of patients 59% 56% —
Dose reduction
% of cycles 31% 2% 27%
Interruption
% of cycles 1% 5% 10%
Delay
% of cycles 19% 33% 22%
Dose reduction, interruption, or delay
% of cycles 43% 36% 49%
Dose reduction, interruption, or delay in > 25% of cycles
% of patients 69% 75% 57%
Completed stage-appropriate therapy
% of patients 73% 44% 67%
DLBCL, diffuse large B cell lymphoma; BL, Burkitt lymphoma;
HL, Hodgkin lymphoma.
Table 2. Clinical Stage and Prognostic Features,








0–1 50% 57% 47%
‡ 2 50% 43% 53%
Ann Arbor stage
I 12% 11% 19%
II — — —
III 19% 33% 37%
IV 69% 56% 44%
Abnormal lactate dehydrogenase 86% 86% 75%
B symptoms 71% 56% 81%
Extranodal sites
0 12% 33% 56%
1 47% 33% 38%
‡ 2 41% 33% 6%
Bone marrow involved (if assessed) 29% 25% 55%
International Prognostic Index











CNS, central nervous system; DLBCL, diffuse large B cell
lymphoma; BL, Burkitt lymphoma; HL, Hodgkin lymphoma.
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treated DLBCL patients without HIV (Table 5). Patients with
HIV were younger and more frequently male and African-
American. Patients with HIV presented more frequently with
stage III or IV disease, abnormal LDH, B symptoms, extra-
nodal involvement, and advanced IPI score. Despite having
less advanced disease, HIV-uninfected patients received more
intensive lymphoma treatment with an equivalent mean
number of chemotherapy cycles, and significantly greater
receipt of rituximab and radiotherapy. Two-year survival af-
ter lymphoma diagnosis was 83% for patients without HIV
compared with 57% for those with HIV ( p = 0.07).
Discussion
We undertook a contemporary description of patients with
HIV-associated lymphoma at a single academic medical
center over an 11-year period. Our results support observa-
tions made elsewhere, and further characterize the interaction
between HIV and lymphoma diagnoses in routine care.
First, our results confirm that presenting CD4 cell count
and HIV RNA values vary by lymphoma histopathologic
subtype. In our sample, BL occurred at higher CD4 cell counts
than other NHL subtypes, similar to recent analysis of the
HIV/AIDS Cancer Match registry.16 A similar inverse corre-
lation of HL risk with CD4 cell count has also been observed,15
with HL incidence unchanged or even increasing in the cART
era.1,2,4 We found no differences in presenting CD4 cell count
between patients with NHL and HL, although this may have
been confounded by more frequent bone marrow involve-
ment among those with HL, particularly as patients with HL
had a higher rate of HIV RNA suppression at lymphoma di-
agnosis than those with NHL. However, declining CD4 cell
count despite continuous HIV RNA suppression in the year
prior to HL diagnosis has also been recently reported from the
COHERE study group.4 Lymphocytopenia occurs frequently
at HL diagnosis even among HIV-uninfected individuals,
correlates with poor survival, and remains poorly understood
with postulated mechanisms including cytokine-induced
immunosuppression and redistribution of lymphocytes from
the periphery into tumor tissue.4,26–31 In addition, the obser-
vation that BL and HL incidence in some epidemiologic
studies is higher in HIV-infected persons with higher CD4
counts also remains largely unexplained. Proposed mecha-
nisms for HL include chemokine-induced recruitment of CD4
cells to germinal centers inhabited by EBV-transformed lym-
phocytes, which may promote survival of malignant lym-
phocytes by protecting them against immune surveillance,
and also interactions between CD40 ligand on activated CD4
cells and CD40 receptors on malignant Reed–Sternberg cells,
which serve to activate the nuclear factor-jB pathway.4,15,29–32
Alternatively, higher CD4 cell counts may lead to increased B
cell activation, thereby increasing the rate at which lympho-
magenic molecular events, such as the c-myc immunoglobulin
translocation event in BL, are generated.16 These putative
mechanisms remain speculative, however, and interactions
between HIV infection and the immune system leading
FIG. 1. Reasons for deviation
from planned cumulative dose




Table 4. Complete Response Rates and Overall Survival After HIV-Associated Lymphoma
All HIV-associated











Complete response 36/62 (58%) 23/44 (52%) 10/16 (62%) 0/12 (0%) 8/9 (89%) 13/17 (76%)
2-year overall survival 29/56 (52%) 19/41 (46%) 8/14 (57%) 0/12 (0%) 5/7 (71%) 10/14 (71%)
5-year overall survival 16/46 (35%) 11/35 (31%) 5/12 (42%) 0/12 (0%) 3/5 (60%) 5/10 (50%)
NHL, non-Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; PCNSL, primary CNS lymphoma; HL, Hodgkin lymphoma.
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ultimately to lymphomagenesis are likely to be complex and
variable across lymphoma subtypes.
Second, patients with HIV-associated lymphoma continue to
present with advanced stage and adverse prognostic features in
the cART era. Eighty-five percent of DLBCL, BL, and HL pa-
tients in our study presented with Ann Arbor stage III or IV
disease, typically accompanied by abnormal LDH, B symp-
toms, frequent bone marrow and extranodal involvement, ad-
vanced IPI score in NHL, and advanced IPS score in HL.
Conversely, 47% of U.S. adults with NHL and 35% with HL
diagnosed between 1999 and 2006 in the Surveillance Epide-
miology and End Results (SEER) database had distant stage III
or IV disease.33,34 Our comparison of DLBCL patients with and
without HIV similarly demonstrated more frequent advanced
stage and adverse prognostic features among those with HIV.
Third, administering chemotherapy to patients with HIV-
associated lymphoma with optimal cumulative dose and dose
intensity is challenging, as patients often present with mod-
erate-to-severe immunosuppression, and may be diagnosed
with HIV in close proximity to their lymphoma diagnosis,
particularly for NHL patients in our study. Sixty-four percent
of DLBCL, BL, and HL patients in our study required dose
reduction, interruption, and/or delay during ‡ 25% of
administered chemotherapy cycles, principally as a result of
infectious complications, febrile neutropenia, and myelosup-
pression. Additionally, fewer DLBCL patients with HIV
received rituximab and radiotherapy compared with HIV-
uninfected patients, despite presenting with more advanced
stage and adverse prognostic features. Rituximab has been
associated with increased risk of neutropenia and infection
without clinical benefit in HIV-associated NHL, particularly
for patients with a CD4 count < 50 cells/ll,35,36 but is also
responsible for a 10–15% increase in long-term survival
among HIV-uninfected patients with DLBCL, with little ad-
ditional toxicity even when applied to elderly patients.37,38
The precise role of rituximab in HIV-associated NHL across
CD4 cell count strata remains to be clarified.
Fourth, administering continuous antiretroviral therapy to
patients with HIV-associated lymphoma is difficult. Patients
frequently experience discontinuity in antiretroviral therapy,
which may promote the development of resistance and
compromise long-term outcomes even among those who are
cured of lymphoma. In our study, regimens containing pro-
tease inhibitors, especially ritonavir, seemed particularly
vulnerable to discontinuity, and preemptive consideration of
alternative regimens, perhaps to include newer agents such as
HIV integrase inhibitors, may be prudent to enhance gastro-
intestinal tolerability and to avoid interactions and over-
lapping toxicities with chemotherapy medications.
We are encouraged that despite advanced initial presen-
tation and significant treatment challenges, 66% of patients
with non-CNS lymphoma survived at least 2 years after
lymphoma diagnosis, with many patients effectively cured
and experiencing long-term survival of more than 5 years.
Nevertheless, survival in our study was lower than is re-
ported for HIV-uninfected patients with lymphoma of com-
parable age and stage, consistent with recent data from the
Center for AIDS Research Network of Integrated Clinical
Systems (CNICS) cohort.8 Five-year survival for HIV-
associated NHL in our population was 31%, compared with
58% for stage III or IV NHL (all ages) and 75% for NHL in
adults < 45 years of age (all stages) in the SEER database,33
although direct comparison of NHL outcomes is limited by
the greater frequency of indolent NHL subtypes among
patients without HIV. Similarly, 5-year survival for HIV-
associated HL in our population was 50%, compared with
74% for stage III or IV HL (all ages) and 92% for HL in adults
< 45 years of age (all stages) in the SEER database.34 Our
comparison of contemporaneously treated DLBCL patients
with and without HIV likewise demonstrated a trend toward
inferior 2-year survival among those with HIV, perhaps me-
diated by more advanced disease and less intensive lym-
phoma therapy. Of all deaths occurring in our study with
ascertainable cause, 73% were due to progressive lymphoma,
suggesting that treatment-related mortality and competing
causes of death are not the main contributors to reduced
overall survival among patients with HIV.
Continued efforts to provide coordinated supportive care
to patients with HIV-associated lymphoma, possibly to in-
clude growth factor support, antibacterial and antifungal
prophylaxis, prompt and continuous antiretroviral therapy,
and expert management of drug interactions between anti-
retroviral and chemotherapy medications, will hopefully re-
sult in clinical outcomes that eventually equal results seen in
HIV-uninfected patients. Additional research to define opti-
mal first-line and salvage lymphoma treatments, including
the role of rituximab and newer agents across CD4 strata,
together with efforts to define optimal antiretroviral therapy,
will hopefully also result in improved outcomes. Our study
also confirms the poor prognosis of HIV-associated PCNSL,
consistent with data from the CNICS cohort,8 even among the
minority of patients with preserved CD4 cell count and HIV
Table 5. Comparison of Patients with Diffuse







Age 42.9 (8.5) 58.3 (16.3) < 0.0001
Male 88% 55% 0.01
Ethnicity












B symptoms present 71% 36% 0.01
‡ 2 extranodal sites 41% 18% 0.04
International Prognostic Index






5.0 (2.6) 5.4 (2.0) 0.6
Received rituximab 59% 87% 0.02
Received radiotherapy 24% 58% 0.03
Mean values given with standard deviations in parentheses.
ECOG, Eastern Cooperative Oncology Group.
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RNA suppression at the time of PCNSL diagnosis. Improved
strategies to prevent, treat, and palliate HIV-associated
PCNSL are urgently needed.
Limitations of our study include the small sample size and
retrospective data collection via abstraction from the medical
record. However, given the inclusion of patients at a single
center with a fully integrated electronic medical record, we
were able to collect accurate, detailed information on the ma-
jority of patients, and the Social Security Death Index was used
to ascertain final vital status for patients lost to follow-up. In
addition, heterogeneity in pathologic descriptions and small
sample size limited our ability to consider morphologic, im-
munophenotypic, and molecular subtypes individually within
larger lymphoma groupings. For instance, we were unable to
assess the influence of plasmablastic morphology or im-
munophenotype within the DLBCL group, a subtype that is
known to occur more frequently in HIV-infected individuals,
and is typically associated with later-stage B cells expressing
plasma cell markers rather than pan-B cell markers as in typical
DLBCL. Plasmablastic DLBCL may be associated with a poorer
response to therapy, and greater frequency of such pathologic
features may contribute to more aggressive disease and poorer
survival in HIV-infected individuals with DLBCL.
In summary, most patients with non-CNS HIV-associated
lymphoma receiving routine care at a single academic medical
center survived at least 2 years after diagnosis. Ongoing ef-
forts to optimize coordinated HIV and lymphoma treatment
will hopefully result in continued survival gains for this
challenging population.
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